Drugs / trivalent seasonal influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT02269852 | Dec 2013 → Apr 2014 | influenza | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01051349 Background | Mar 2010 → Aug 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trivalent seasonal influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01051349 ↗ |
| Modality | Vaccine | “trivalent seasonal influenza vaccine” NCT01051349 ↗ |